Literature DB >> 27538907

Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.

Kei Takayama1, Hiroki Kaneko2, Keiko Kataoka1, Shinji Ueno1, Piao Chang-Hua1, Yasuki Ito1, Hiroko Terasaki1.   

Abstract

BACKGROUND: To compare short-term outcomes of intravitreal aflibercept injection (IAI) with or without initial photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) using focal macular electroretinography (FMERG).
DESIGN: Observation case series.
METHODS: Twelve patients (6 males, 6 females; 12 eyes) with naïve PCV received 3 initial IAIs and a single session of PDT 3 days after the first IAI (combination group), and 13 patients (7 males, 6 females; 13 eyes) with naïve PCV received 3 initial IAIs only (IAI group) were retrospectively observed. Changes in visual acuity, central retinal thickness (CRT), central choroidal thickness (CCT), and FMERG parameters (FMERGs) were compared.
RESULTS: The combination group showed improved visual acuity after the second and third IAI (P = 0.040, 0.019, respectively); both groups showed reduced CRT after the first IAI (P < 0.01, each). Only the combination group showed reduced CCT after the third IAI (P = 0.031). The FMERGs of the IAI group showed improved amplitudes of a-waves after the third IAI (P = 0.026) and of b-waves after the first and third IAI (P = 0.034, < 0.01, respectively); the combination group did not show improvement. The implicit times of the a- and b-waves were not changed in either group.
CONCLUSIONS: Combination therapy and IAI monotherapy each improved visual acuity and retinal structure to a similar degree; combination therapy reduced choroidal thickness but did not improve FMERGs in the short term.

Entities:  

Keywords:  Aflibercept; Focal macular electroretinogram; Photodynamic therapy; Polypoidal choroidal vasculopathy

Mesh:

Substances:

Year:  2016        PMID: 27538907     DOI: 10.1007/s00417-016-3468-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

Review 1.  Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization.

Authors:  H Terasaki
Journal:  Nagoya J Med Sci       Date:  2001-05       Impact factor: 1.131

2.  Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Masaaki Saito; Tetsuju Sekiryu
Journal:  Am J Ophthalmol       Date:  2011-02-04       Impact factor: 5.258

3.  Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.

Authors:  Hideki Koizumi; Mariko Kano; Akiko Yamamoto; Masaaki Saito; Ichiro Maruko; Tetsuju Sekiryu; Annabelle A Okada; Tomohiro Iida
Journal:  Br J Ophthalmol       Date:  2015-03-16       Impact factor: 4.638

4.  EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Authors:  Adrian Koh; Won Ki Lee; Lee-Jen Chen; Shih-Jen Chen; Yehia Hashad; Hakyoung Kim; Timothy Y Lai; Stefan Pilz; Paisan Ruamviboonsuk; Erika Tokaji; Annemarie Weisberger; Tock H Lim
Journal:  Retina       Date:  2012-09       Impact factor: 4.256

Review 5.  Aflibercept for age-related macular degeneration: a game-changer or quiet addition?

Authors:  David J Browning; Peter K Kaiser; Philip J Rosenfeld; Michael W Stewart
Journal:  Am J Ophthalmol       Date:  2012-08       Impact factor: 5.258

6.  Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.

Authors:  Timothy Y Y Lai; Gary K Y Lee; Fiona O J Luk; Dennis S C Lam
Journal:  Retina       Date:  2011-09       Impact factor: 4.256

7.  Focal macular electroretinograms in eyes with wet-type age-related macular degeneration.

Authors:  Hiroaki Nishihara; Mineo Kondo; Kohei Ishikawa; Tadasu Sugita; Chang-Hua Piao; Yoshiharu Nakamura; Hiroko Terasaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-11       Impact factor: 4.799

8.  Asymmetry of focal ERG in human macular region.

Authors:  Y Miyake; N Shiroyama; M Horiguchi; I Ota
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-08       Impact factor: 4.799

Review 9.  Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies.

Authors:  Wei Wang; Miao He; Xiulan Zhang
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

Review 10.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10
View more
  7 in total

1.  Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.

Authors:  Tsutomu Sakai; Noriko Kato; Masaomi Kubota; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-11       Impact factor: 3.117

2.  Nutritional Supplementation Inhibits the Increase in Serum Malondialdehyde in Patients with Wet Age-Related Macular Degeneration.

Authors:  Toshiyuki Matsuura; Kei Takayama; Hiroki Kaneko; Fuxiang Ye; Hiroshi Fukukita; Taichi Tsunekawa; Keiko Kataoka; Shiang-Jyi Hwang; Yosuke Nagasaka; Yasuki Ito; Hiroko Terasaki
Journal:  Oxid Med Cell Longev       Date:  2017-01-24       Impact factor: 6.543

3.  Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Kyoko Hattori; Eimei Ra; Taichi Tsunekawa; Hiroshi Fukukita; Fuminori Haga; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

4.  Novel Classification of Early-stage Systemic Hypertensive Changes in Human Retina Based on OCTA Measurement of Choriocapillaris.

Authors:  Kei Takayama; Hiroki Kaneko; Yasuki Ito; Keiko Kataoka; Takeshi Iwase; Tetsuhiro Yasuma; Toshiyuki Matsuura; Taichi Tsunekawa; Hideyuki Shimizu; Ayana Suzumura; Eimei Ra; Tomohiko Akahori; Hiroko Terasaki
Journal:  Sci Rep       Date:  2018-10-11       Impact factor: 4.379

5.  Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy.

Authors:  I-Hsin Ma; Yun Hsia; Yi-Ting Hsieh; Tzyy-Chang Ho; Tso-Ting Lai; Chung-May Yang; Chang-Hao Yang
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

6.  Microperimetry and multimodal imaging in polypoidal choroidal vasculopathy.

Authors:  Jennifer H Acton; Ken Ogino; Yumiko Akagi; John M Wild; Nagahisa Yoshimura
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

7.  Outcomes of 25-Gauge Vitrectomy for Tractional and Nontractional Diabetic Macular Edema with Proliferative Diabetic Retinopathy.

Authors:  Hideaki Someya; Kei Takayama; Masaru Takeuchi; Hiroshi Yokoyama; Takeshi Kimura; Masakazu Morioka; Yoshihiro Takamura; Seiji Sameshima; Tetsuo Ueda; Nahoko Ogata; Maki Tashiro; Shigehiko Kitano; Taiji Sakamoto
Journal:  J Ophthalmol       Date:  2019-12-11       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.